Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research  How it helps Latest publication
Teniposide
Potential treatment - theoretical effect Experimental Antiviral Apr/12/2021
Apilimod
Potential treatment - pre-clinical evidence Experimental Antiviral Aug/06/2020
LbuCas13a N3.2
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/03/2021
Birinapant
Potential treatment - theoretical effect Experimental Antiviral Aug/20/2020
SARS-CoV-2 RBD-Fc
Potential treatment - pre-clinical evidence Experimental Vaccine Nov/27/2020
Vacuolin-1
Potential treatment - pre-clinical evidence Experimental Antiviral Aug/06/2020
VHH-72-VHH-72
Potential treatment - pre-clinical evidence Experimental Antiviral May/05/2020
Narasin
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/25/2020
5-[(Carbamoylcarbamoyl)amino]-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/02/2021
E-3G9
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/27/2021
P5A-1B6
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/17/2021
VHH-72-Fc
Potential treatment - pre-clinical evidence Experimental Antiviral May/05/2020
A-2F1
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/27/2021
Eicosatetraynoic acid
Potential treatment - theoretical effect Experimental Other treatment Jun/27/2020
Aclarubicin
Potential treatment - theoretical effect Experimental Antiviral Oct/19/2020
Maduramicin
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/15/2021
1-Benzyl-3-[[3-[3-[4-[4-(hydroxymethyl)phenyl]-6-[(4-methyl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3-dioxan-2-yl]phenyl]phenyl]methyl]urea
Potential treatment - theoretical effect Experimental Antiviral Oct/20/2020
Faldaprevir
Potential treatment - theoretical effect Experimental Antiviral Oct/19/2020
N-[3-[4-[4-(Hydroxymethyl)phenyl]-6-[[2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methyl]-1,3-dioxan-2-yl]phenyl]acetamide
Potential treatment - theoretical effect Experimental Antiviral Oct/20/2020
NIH-CoVnb-112
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/22/2020